Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
Mahdi Al DhafiriFlore Sicre de FontbruneEduardo MarinhoLydia DeschampsJulie Di-LuccaBeatrice CrickxVincent DescampsPublished in: Clinical case reports (2019)
The primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) has a poor prognosis. R-CHOP with or without radiotherapy is the available recommendations for first-line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second-line treatment of relapsed PCDLBCL-LT.
Keyphrases
- diffuse large b cell lymphoma
- poor prognosis
- multiple myeloma
- epstein barr virus
- long non coding rna
- newly diagnosed
- clinical practice
- stem cell transplantation
- randomized controlled trial
- early stage
- systematic review
- radiation therapy
- chronic lymphocytic leukemia
- radiation induced
- locally advanced
- squamous cell carcinoma
- acute lymphoblastic leukemia
- acute myeloid leukemia